HealthQuill diabetes
AstraZeneca, a British-Swedish pharmaceutical company, has signed a deal, worth more than $2 billion, with Quell Therapeutics to develop cell therapies for treating autoimmune diseases.
Drugs Health Pharma

AstraZeneca signs $2 billion deal for autoimmune diseases

HQ Team June 9, 2023: AstraZeneca, a British-Swedish pharmaceutical company, has signed a deal, worth more than $2 billion, with Quell Therapeutics to.

Read More
Diabetes
Drugs Health Medical

Oral semaglutide reduces HbA1c, weight in Type 2 diabetics, study reveals

HQ Team June 8, 2023: A new study analyzing the PIONEER (Peptide Innovation for Early Diabetes Treatment) clinical trials data has revealed the.

Read More
A study to find solutions for treating two new variations of diabetes, type 4 and type 5, is underway in US research institutions as the overall disease population is expected to reach 783 million people by 2045.
Drugs Health Medical Pharma

Type 4, and 5, diabetes in adults, children often misdiagnosed

HQ Team May 22, 2023: A study to find solutions for treating two new variations of diabetes, type 4 and type 5, is.

Read More
Eli Lily sold its sugar-controlling drug to Amphastar Pharmaceuticals for $1.07 billion.
Drugs Health Pharma

Eli Lilly to sell diabetic nasal drug to Amphastar for $1.07 billion 

Eli Lily sold its sugar-controlling drug to Amphastar Pharmaceuticals for $1.07 billion.

Read More
Cipla Ltd has agreed with Novartis Pharma AG to market and manufacture the Swiss-based company’s Galvus brand for treating type 2 diabetes.
Drugs Health Medical Pharma

Cipla, Novartis team up to make, market anti-diabetic drug

HQ Team April 10, 2023: Cipla Ltd has agreed with Novartis Pharma AG to market and manufacture the Swiss-based company’s Galvus brand for.

Read More
Sanofi, a French pharmaceutical major, announced it would slash the price of insulin, Lantus, by 78% for all U.S. patients with commercial insurance.
Drugs Medical Pharma

Sanofi lowers Lantus insulin costs by 78% in U.S. market

Sanofi, a French pharmaceutical major, announced it would slash the price of insulin, Lantus, by 78% for all U.S. patients with commercial insurance.

Read More
India's Dr. Reddy's Laboratories has divested "certain" non-core dermatology brands of the company to Eris Lifesciences for INR 2.7 billion.
Drugs Pharma

Dr. Reddy divests dermatology brands to Eris for INR 2.7b

India's Dr. Reddy's Laboratories has divested "certain" non-core dermatology brands of the company to Eris Lifesciences for INR 2.7 billion.

Read More
Denmark's Novo Nordisk plans to effect a 75% cut in insulin prices in the U.S. market by January 1, 2024.
Drugs Pharma

Novo Nordisk follows Eli Lilly on insulin price cuts

Denmark's Novo Nordisk plans to effect a 75% cut in insulin prices in the U.S. market by January 1, 2024.

Read More
Eli Lilly will invest an additional $450 million to expand its manufacturing capacity at Research Triangle Park facility in North Carolina.
Drugs Medical Pharma

Sanofi acquires Provention Bio for $2.9 billion to boost its diabetes portfolio

Sanofi acquires Provention Bio, and its TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).

Read More
Zydus Lifesciences, a subsidiary of Zydus Pharmaceuticals US, has received two tentative FDA approvals, one for treating type 2 diabetes and the other for shingles.
Drugs Pharma

Zydus gets FDA green light for drugs to treat diabetes, shingles

Zydus Lifesciences, a subsidiary of Zydus Pharmaceuticals US, has received two tentative FDA approvals, one for treating type 2 diabetes and the other.

Read More